METHODS	Results - The topiramate group showed a reduction in the mean ( + / - SD ) of monthly migraine frequency from 6.07 ( + / -1.89 ) to 1.83 ( + / -1.39 ) episodes per month , headache intensity from 7.1 ( + / -1.45 ) to 3.67 ( + / -2.1 ) based on the Visual Analog Scale , and headache duration from 16.37 ( + / -7.26 ) to 6.23 ( + / -5.22 ) hours ( P < 0.001 ) .\